MENLO PARK, Calif. — AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and pharmacokinetics of epetraborole, an orally administered inhibitor of leucyl-tRNA synthetase...

CAMBRIDGE, England & BOSTON, Mass.— CellCentric, a clinical-stage biotechnology company developing inobrodib as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, today announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating inobrodib 20 mg in combination with standard doses of pomalidomide (pom) and dexamethasone...

IRVINE, Calif. — Ambros Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new U.S. patent application covering methods of selectively treating patients having Complex Regional Pain Syndrome Type 1 (CRPS-1), an orphan designated disease. The granting of this...